MDACC Study No:2011-0681 ( NCT No: NCT01402440)
Title:An Open-Label, Single-arm, Phase I study of AEB071 (a Protein Kinase C Inhibitor) in Patients with CD79-mutant Diffuse Large B-Cell Lymphoma
Principal Investigator:Nathan Fowler
Treatment Agent:AEB071
Study Status:Terminated
Study Description:The goal of this clinical research study is to test if the study drug AEB071
has any activity against your cancer. It also will help to determine the
highest dose of AEB071 that can be given safely without unacceptable side
effects. The study will also examine how much and for how long AEB071 stays in
your blood.

To assess what effect the drug is having on your cancer, biomarker studies will
also be included in this trial. Biomarkers are important biological
‘indicators’ that can be measured from blood and tumor tissues. Biomarker
samples will be collected before you start your treatment with study drug in
this trial and then at various times afterwards. With these samples,
researchers can make a comparison to assess whether the study drug is having
any effect on your cancer.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I
Treatment Agents:AEB071
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Nathan Fowler
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults